Preoperative/neoadjuvant therapy in pancreatic cancer

In research published this week in PLoS Medicine, Jorg Kleeff from Technische Universitat Munchen, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protocols. The authors systematically reviewed studies concerning the effects of neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer.

Read the whole article on Physorg

More from Physorg